# Implementing a Low-Threshold Hepatitis C Treatment in a Jail Setting

> **NIH NIH R34** · RHODE ISLAND HOSPITAL · 2024 · $252,042

## Abstract

PROJECT SUMMARY
 Carceral facilities, particularly jails, present a unique opportunity to address the public health crisis of
hepatitis C virus (HCV) and HIV among people who inject drugs (PWID). With two-thirds of PWID experiencing
incarceration in the United States and a high HCV/HIV seroprevalence in these settings, jails become a critical
access point for addressing the hepatitis C epidemic. Recent studies demonstrate the potential for low-barrier
HCV treatment models (e.g., the “minimal monitoring” MINMON protocol) to cure hepatitis C, even among
high-risk patient populations including those with active drug use. Despite this, HCV treatment in jails, which
are characterized by high turnover and short-term stays, is rare. This represents a missed public health
opportunity, contrasting with the success of HCV treatment seen in long-term prison facilities.
 This planning grant seeks to fill this critical gap by piloting an innovative, low-barrier HCV treatment
strategy in a jail setting. Coined “MINMON-J,” this approach modifies the MINMON protocol for use in jails.
MINMON-J incorporates take-home HCV medication and collaboration with a community Transitions Clinic,
leveraging community health workers (CHWs) to support patient navigation and post-release linkage to care.
 In Aim 1, the study aims to evaluate the feasibility and effectiveness of MINMON-J through a single-arm
pilot trial involving jailed PWID with HCV mono-infection or co-infection with HIV. Participants will receive rapid
HCV treatment initiation while incarcerated. Individuals released before treatment will receive all remaining
medication and CHW-facilitated peer navigation. Outcomes, assessed using the RE-AIM/PRISM framework,
will include HCV cure rates and various implementation outcomes to inform a subsequent stepped-wedge
Type 1 hybrid effectiveness-implementation trial.
 In Aim 2, in-depth interviews will help characterize facilitators and barriers to low-barrier HCV treatment
in a jail to refine the approach for broader implementation in similar settings.
 This research serves to establish a transformative, community-informed strategy for HCV treatment in
jail settings, addressing a significant public health need. The outcomes of this pilot study have the potential to
shift paradigms in HCV elimination strategies, particularly for PWID and people living with HIV, aligning with
the goals of national health agencies, and contributing to the broader effort of HCV elimination.

## Key facts

- **NIH application ID:** 11007380
- **Project number:** 1R34DA061732-01
- **Recipient organization:** RHODE ISLAND HOSPITAL
- **Principal Investigator:** Justin Berk
- **Activity code:** R34 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $252,042
- **Award type:** 1
- **Project period:** 2024-09-15 → 2027-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/11007380

## Citation

> US National Institutes of Health, RePORTER application 11007380, Implementing a Low-Threshold Hepatitis C Treatment in a Jail Setting (1R34DA061732-01). Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/grant/nih/11007380. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*